Results 11 to 20 of about 51,607 (296)
HemaSphere, 2022 Resistance to cytarabine is a key problem in the treatment of acute myeloid leukemia (AML). To understand the molecular biology of resistance to cytarabine, a viability-based chemosensitizer screen was utilized. We screened synthetic lethal targets using
Miriam Rehberger +7 more
doaj +1 more source
Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
Nature Communications, 2022 Devimistat is a TCA cycle inhibitor. A previously completed phase I study of devimistat in combination with cytarabine and mitoxantrone in patients with relapsed or refractory AML showed promising response rates.
Rebecca G. Anderson +13 more
semanticscholar +1 more source
Cancers, 2021 Simple Summary In this review, the authors propose a crosswise examination of cytarabine-related issues ranging from the spectrum of clinical activity and severe toxicities, through updated cellular pharmacology and drug formulations, to the genetic ...
R. Di Francia +10 more
semanticscholar +1 more source
Brain and Behavior, Volume 12, Issue 12, December 2022., 2022 Abstract Objective Childhood cancer and cancer‐related treatments disrupt brain development and maturation, placing survivors at risk for cognitive late effects. Given that assessment tools vary widely across researchers and clinicians, it has been daunting to identify distinct patterns in outcomes across diverse cancer types and to implement ...
Julie A. Trapani, Donna L. Murdaugh
wiley +1 more source
Gels, 2022 In the current study, a pH sensitive intelligent hydroxypropyl–β–cyclodextrin-based polymeric network (HP-β-CD-g-MAA) was developed through a solution polymerization technique for site specific delivery of cytarabine in the colonic region.
Nighat Batool +7 more
doaj +1 more source
Blood Cancer Discovery, 2021 Immune suppression, exhaustion, and senescence are frequently seen throughout disease progression in acute myeloid leukemia (AML). We conducted a phase II study of high-dose cytarabine followed by pembrolizumab 200 mg i.v. on day 14 to examine whether PD-
J. Zeidner +21 more
semanticscholar +1 more source
Cancer Communications, Volume 42, Issue 12, Page 1387-1402, December 2022., 2022 Abstract Background Patients with refractory or relapsed acute myeloid leukemia (AML) have poor survival, necessitating the exploration of optimized therapeutic strategy. Here, we aimed to investigate clinical outcomes and health‐related quality of life (HR‐QoL) after total therapy, which included allogeneic hematopoietic stem cell transplantation ...
Chen‐hua Yan +13 more
wiley +1 more source
Molecular and cellular paradigms of multidrug resistance in cancer
Cancer Reports, Volume 5, Issue 12, December 2022., 2022 Abstract Background The acquisition of resistance to chemotherapy is a major hurdle in the successful application of cancer therapy. Several anticancer approaches, including chemotherapies, radiotherapy, surgery and targeted therapies are being employed for the treatment of cancer.
Foram U. Vaidya +6 more
wiley +1 more source
Orphanet Journal of Rare Diseases, 2022 Background Non-Langerhans cell histiocytosis, including Erdheim–Chester disease (ECD), Rosai–Dorfman disease (RDD), indeterminate cell histiocytosis (ICH), and unclassified histiocytosis, is a rare disorder lacking a standard treatment strategy.
Ting Liu +7 more
doaj +1 more source
Adult patients with Ph+ ALL benefit from conditioning regimen of medium‐dose VP16 plus CY/TBI
Hematological Oncology, Volume 40, Issue 5, Page 1041-1055, December 2022., 2022 Abstract The medium‐dose etoposide (VP16) added on cyclophosphamide (CY)/total body irradiation (TBI) is one of the intensified myeloablative conditioning regimens used in allogenic hematopoietic stem cell transplantation (allo‐HSCT) for acute lymphoblastic leukemia (ALL).
Mari Morita‐Fujita +18 more
wiley +1 more source